Today: 6 February 2026
Subscribe
Browse Category

NASDAQ:AKRO News 15 October 2025 - 14 December 2025

Novo Nordisk Stock (NOVO-B, NVO) Update Dec 14, 2025: Wegovy 7.2 mg Tailwind, Ozempic India Launch, Akero Deal — Outlook for the Week Ahead

Novo Nordisk Stock (NOVO-B, NVO) Update Dec 14, 2025: Wegovy 7.2 mg Tailwind, Ozempic India Launch, Akero Deal — Outlook for the Week Ahead

Updated: December 14, 2025 (Sunday) Novo Nordisk A/S shares ended this week with a rebound after a choppy start, as investors weighed three heavyweight catalysts: (1) the EU regulator’s support for a higher-dose Wegovy, (2) the long-telegraphed India launch of Ozempic at a sharply lower price point, and (3) the closing of Novo’s multibillion-dollar acquisition of Akero Therapeutics to expand…
14 December 2025
·······
Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Deal Details: Novo Licenses Omeros’s MASP-3 Inhibitor On Oct. 15, Novo Nordisk and Seattle-based Omeros announced a definitive asset purchase and license agreement. Under the terms, Novo gains exclusive global rights to zaltenibart (OMS906) for all indications. Omeros will receive $340 million up front and near-term milestones, plus up to $2.1 billion total with development and sales milestones and tiered royalties…
15 October 2025
······

Stock Market Today

  • Senvest Capital (TSE:SEC) Stock Rises Above 50-Day Moving Average
    February 6, 2026, 9:30 AM EST. Shares of Senvest Capital Inc (TSE:SEC) crossed above their 50-day moving average of C$369.76 on Thursday, reaching a high of C$385.00. The company, with a market cap near C$935 million and a low beta of -0.16 indicating limited market volatility, recently posted a strong quarter with earnings per share (EPS) of C$70.97 and revenue of C$536.92 million. Senvest Capital manages a diverse portfolio primarily in U.S. equities and real estate. Despite the momentum, the stock holds a Hold rating from analysts, who currently favor other stocks. The firm's 200-day average stands at C$361.35, offering a broader trend perspective. Trading volume was modest at 750 shares. This movement reflects nuanced investor response following solid financial results as the stock tests technical resistance levels.
Go toTop